Genomic Analysis Identifies Targets of Convergent Positive Selection in Drug Resistant Mycobacterium tuberculosis

View/ Open
Author
Shapiro, B Jesse
Sultana, Razvan
Jacobson, Karen R
Victor, Thomas C
Warren, Robin M
Streicher, Elizabeth M
Calver, Alistair
Sloutsky, Alex
Kaur, Devinder
Posey, Jamie E
Plikaytis, Bonnie
Oggioni, Marco R
Gardy, Jennifer L
Johnston, James C
Rodrigues, Mabel
Tang, Patrick K C
Kato-Maeda, Midori
Muddukrishna, Bhavana
Kreiswirth, Barry N
Kurepina, Natalia
Galagan, James
Gagneux, Sebastien
Birren, Bruce
Lander, Eric S
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1038/ng.2747Metadata
Show full item recordCitation
Farhat, M. R., B. J. Shapiro, K. J. Kieser, R. Sultana, K. R. Jacobson, T. C. Victor, R. M. Warren, et al. 2013. “Genomic Analysis Identifies Targets of Convergent Positive Selection in Drug Resistant Mycobacterium tuberculosis.” Nature genetics 45 (10): 10.1038/ng.2747. doi:10.1038/ng.2747. http://dx.doi.org/10.1038/ng.2747.Abstract
Mycobacterium tuberculosis is successfully evolving antibiotic resistance, threatening attempts at tuberculosis epidemic control. Mechanisms of resistance, including the genetic changes favored by selection in resistant isolates, are incompletely understood. Using 116 newly and 7 previously sequenced M. tuberculosis genomes, we identified genomewide signatures of positive selection specific to the 47 resistant genomes. By searching for convergent evolution, the independent fixation of mutations at the same nucleotide site or gene, we recovered 100% of a set of known resistance markers. We also found evidence of positive selection in an additional 39 genomic regions in resistant isolates. These regions encode pathways of cell wall biosynthesis, transcriptional regulation and DNA repair. Mutations in these regions could directly confer resistance or compensate for fitness costs associated with resistance. Functional genetic analysis of mutations in one gene, ponA1, demonstrated an in vitro growth advantage in the presence of the drug rifampicin.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887553/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12152881
Collections
- FAS Scholarly Articles [18056]
- HMS Scholarly Articles [18305]
- SPH Scholarly Articles [6402]
Contact administrator regarding this item (to report mistakes or request changes)